Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Clin Cancer Res. 2012 Oct 23;18(24):6784–6791. doi: 10.1158/1078-0432.CCR-12-1785

Table 2.

Receptor status of primary versus post-trastuzumab tumors

Treated cohort of HER2+ lesions Untreated cohort of HER2+ lesions
Primary or pre-therapy Secondary or post-therapy
HER2
pos 63/63 (100%) 53/60 (88%) 73/73 (100%)
neg - 7/60 (12%) -
na - 3/63 -
ER
pos 31/63 (49%) 32/59 (54%) 41/73 (56%)
neg 32/63 (51%) 27/59 (46%) 32/73 (44%)
na - 4/63 (6%) -
PR
pos 15/63 (24%) 14/58 (24%) 30/73 (41%)
neg 48/63 (76%) 44/58 (76%) 43/73 (59%)
na - 5/63 (8%) -